Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Endeavor Health
With
Shire
This is a double blind randomized placebo controlled pilot study. Subjects with Chronic Kidney Disease ( CKD) stages 3-5 who are not undergoing renal replacement therapy and have not been started on phosphate binders will be randomized to either lanthanum carbonate 1500 mg daily or placebo for a 60 day treatment period. Patient doses will be increased up to a maximum dose of 3000 mg if the serum phosphate is greater than 5.5 mg/dL.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Males and non-pregnant females ages 18 years of age or older
Estimated glomerular filtration rate (GFR) between 15-60 ml/min/1.73m
Serum phosphate \> 3.5 mg/dL
Fibroblast growth factor 2 (FGF2) \> 100 relative units per milliliter (RU/mL)
Corrected serum calcium \>8.0mg/dL
You may not be if
Current use of a phosphate binder
Corrected serum calcium \<8.0mg/dL
Current use of prescription-based vitamin D therapy
Acute kidney injury in last 3 months
Significant GI disorder
History of allergic reaction or sensitivity to lanthanum carbonate
History of non compliance with visits or medications that preclude study compliance in the opinion of the investigator
Pregnant or able to become pregnant and unwilling to use a birth control method considered reliable by the principal investigator
